Corrections and changes

112 November 2026

• Added this page and About this reference: who compiles the site, how it is made, how corrections are handled, privacy and contact.
• The data may now be reused under the Creative Commons Attribution 4.0 license, and the scripts and the catalog were published at github.com/agilepeter/myoepithelial-carcinoma.
• Translations. A separate model translated the Spanish, Chinese and Japanese pages back into English without seeing the original, and the results were compared. 29 sentences were corrected. In Chinese and Japanese, a word used for “patient organization” also means “tissue”. The Chinese said a tumor had “infiltrated the adjacent margin” where the English says “invasion close to the margin”. Every number matched the English.
• Dates. “Retrieved”, the date on which trial status was recorded and the date of the source check had been following the day the pages were built. Each now shows the day the thing happened.
• An email address quoted inside a public dataset description was removed from the open data.
• The machine-readable description of the main page no longer says the page was “last reviewed”. No clinician has reviewed it.
• The author’s name at the foot of each page now goes to his account of why he built the site. It had gone to his profile on another part of staas.fund.
• Contact moved from a general contact page to an address for this reference.
• Reading on a phone. A table that holds sentences is now set out as one record under another, so no column is cut off. Chart labels are larger, and the menus open across the screen. Two text colors were darkened to meet the contrast guideline for readers with low vision.
• The image shown when a link is shared said “every published paper”. It now gives the count of papers that name the disease. The catalog is not complete, as Method and limits says.

211 November 2026

• The reference was published.
• Source check. A model checked 141 cited claims against their sources: 65 against the full paper and 76 against the abstract. Thirteen were wrong or not supported by the source cited. The corrections follow.
• “40 to 45% of tumors recurred” in the adult soft-tissue series was a figure that paper quotes from earlier work. It was replaced with the series’ own result: 13 of 24 patients (54.2%) relapsed, 3 locally and 10 with metastases¹.
• Survival at 15 years in the salivary registry study was changed from 39% to 38%, the figure in the full text. The shares with lymph node and distant spread now say they are of patients with a recorded stage, and the benefit of radiotherapy now says it appeared only after adjustment².
• The proposal that some of these tumors are sarcomas is now limited, as in the paper, to malignant tumors with EWSR1 or FUS fusions. “Biologically unrelated” became “epigenetically unrelated”, and the outcomes table now says that 69 of the 185 tumors had survival data³.
• A figure of 27% from a salivary series is now given as 12 of the 44 patients with follow-up⁴.
• ATF1 as a partner gene of EWSR1 is now cited to the paper that reports it⁵.
• The definition, the older name, the registry code and the separation from epithelial-myoepithelial carcinoma are each cited to a source that states them. The code is given as 8982, without “/3”.
• Two statements about the skin form were removed because the sources do not make them: that it is the rarest and least studied form, and that it was recognized only in 2003 and 2004⁶⁷⁸.
• “The largest soft-tissue series” became “a 101-tumor soft-tissue series”⁹.
• “Diagnosis often involves a second opinion” became the finding it rested on: in one series most cases had first been given a different diagnosis¹⁰.
• The National Cancer Database survival figures are no longer called overall survival. The abstract does not say which kind of survival they are¹¹.
• The incidence rates for 2012 were added from the full text of the registry study¹².

3References